Showing 3751-3760 of 6978 results for "".
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on t
- Povorcitinib Shows Efficacy and Safety in Patients with Prurigo Nodularishttps://practicaldermatology.com/news/study-povorcitinib-safe-and-effective-for-prurigo-nodularis/2462426/The oral JAK1 inhibitor povorcitinib was shown to improve itch in prurigo nodularis, and also met its primary endpoints, according to new phase 2 data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the study enrolled 146 participants and
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- ADORING Trials: Tapinarof Cream, 1% Effective in Patients with Skin of Colorhttps://practicaldermatology.com/news/adoring-trials-tapinarof-effective-in-patients-with-skin-of-color/2462266/In a patient population with diverse skin tones, tapinarof cream, 1% (VTAMA®, Dermavant) was shown to have significant efficacy in both adults and children as young as 2 years of age with atopic dermatitis (AD), according to new results presented at the 2024 American Academy of Dermatology Annual
- 595-nm Pulsed Dye Laser with 1565-nm Nonablative Fractional Laser Safe, Effective for Acnehttps://practicaldermatology.com/news/treatment-of-erythematous-acne-scars-using-595-nm-pulsed-dye-laser-combined-with-1565-nm-resurfx-nonablative-fractional-laser/2462257/The use of a 595-nm pulsed dye laser (PDL) and 1565-nm nonablative fractional laser (NAFL) was seen as safe and efficacious in patients with acne vulgarism, according to a new study in the Journal of Cosmetic Dermatology. "Acne erythema has been considered simple ery
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A
- Fear of Cancer Recurrence Elevated Among Survivors of Localized Cutaneous Melanoma: Analysishttps://practicaldermatology.com/news/lived-experiences-and-fear-of-cancer-recurrence-among-survivors-of-localized-cutaneous-melanoma/2462249/Patients who suffer from localized cutaneous melanoma report high levels of fear of cancer recurrence, according to a new analysis. Researchers investigating the psychological well-being and fear of cancer recurrence among survivors of localized cutaneous melanoma in the United States ev
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Study Highlights Fatigue Experienced by Psoriasis Patientshttps://practicaldermatology.com/news/study-highlights-fatigue-experienced-in-psoriasis/2462247/A new analysis in the Journal of the American Academy of Dermatology sought to tease out drivers of fatigue in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Researchers for the study examined various factors contributing to fatigue in these individuals using
- Intravenous Ertapenem Shows Improvement in Hidradenitis Suppurativahttps://practicaldermatology.com/news/intravenous-ertapenem-for-hidradenitis-suppurativa-efficacy-and-patient-satisfaction/2462245/Results from a new analysis indicated that intravenous ertapenem was associated with improvements in markers of hidradenitis suppurativa (HS) and was linked with increased patient satisfaction. The retrospective analysis included medical records of 98 patients with HS who